ConductScience.org, home

Comparison · NCT00530803-deaths

EMLA Cream vs Synera Patch: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. EMLA Cream vs Synera Patch: deaths from any cause. Trial comparisons, record NCT00530803-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00530803-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 100.000000000000000006940.0713wilson
Risk in group 200.000000000000000006940.0713wilson
Risk difference, group 1 minus group 20-0.07130.0713newcombe hybrid score
Risk ratio, group 1 over group 2loga group has no participants with the outcome
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zero
Number needed to harmfrom the risk difference intervalthe two groups' risks are equal

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1EMLA Cream
Participants will have a dose of EMLA Cream applied to the venipuncture site 1 hour before the procedure. Dosage based on age and weight: 4-6 years old and heavier than 10kg will receive 10g of EMLA; 7-12 years old and more than 20kg will receive 20g of EMLA.~EMLA Cream: 60 minutes x1
050EG000
Group 2Synera PatchParticipants will have a Synera Patch applied to the venipuncture site 20 minutes prior to the procedure.~Synera Patch: 20 minutes x1050EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Investigators monitored for adverse events during procedure and up to 20 minutes after removal of topical anesthetic.

Source ClinicalTrials.gov

Trial

Title
The Efficacy of EMLA Cream vs. Synera Patch for Pain Reduction During Venipuncture in Children
NCT number
NCT00530803
Phases
PHASE2
Conditions
Pain, Needle Phobia
Interventions
EMLA Cream, Synera Patch
Lead sponsor
Montefiore Medical Center
Results first posted
2018-08-31

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00530803-deaths